December 8, 2007

Use of 70-gene Signature to Predict Prognosis of Patients with Node-Negative Breast Cancer: A Prospective Community-Based Feasibility Study (RASTER)

PUBLICATION: 
Lancet Oncol. 2007 Dec;8(12):1079-1087. doi: 10.1016/S1470-2045(07)70346-7. Epub 2007 Nov 26.

AUTHORS: 
Bueno-de-Mesquita J.M., van Harten W.H., Retel V.P., van’t Veer L.J., van Dam F.S., Karsenberg K., Douma K.F., van Tinteren H., Peterse J.L., Wesseling J., Wu T.S., Atsma D., Rutgers E.J., Brink G., Floore A.N., Glas A.M., Roumen R.M., Bellot F.E., van Krimpen C., Rodenhuis S., van de Vijver M.J., Linn S.C.

SUMMARY: 
Initial review of RASTER, decision impact review. A microarray-based 70-gene prognosis signature might improve the selection of patients with node-negative breast cancer for adjuvant systemic treatment. The main aims of this MicroarRAy PrognoSTics in Breast CancER (RASTER) study were to assess prospectively the feasibility of implementation of the 70-gene prognosis signature in community-based settings and its effect on adjuvant systemic treatment decisions when considered with treatment advice formulated from the Dutch Institute for Healthcare Improvement (CBO) and other guidelines.

Read more: Use of 70-gene Signature to Predict…_Bueno-de-Mesquita et al_Lancet Oncol. 2007